EUVIMEDEUVIMED entdecken
Crossref

Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: Design and Rationale of the PRAISE-MR Trial

Sebastiaan Dhont, Sara Moura Ferreira, Xavier Galloo, Pieter Martens, Evelyne Meekers, Katrien Tartaglia, Sébastien Deferm, Lieven Herbots, Wilfried Mullens, Frederik H Verbrugge, Jan Verwerft, Philippe B Bertrand

Journal of Cardiac Failure · 2025

DOI: 10.1016/j.cardfail.2025.05.019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiac Failure, 2025. Verfasst von Sebastiaan Dhont und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Hospital Oost-Limburg, Genk, Belgium; Doctoral School of Medicine and Life Sciences, Limburg Clinical Research Center, Facu…. Hauptthemen laut MEDLINE: Heart Failure, Mitral Valve Insufficiency, Stroke Volume, Aminobutyrates. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: FWO.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Secondary or functional mitral regurgitation (FMR) of atrial origin is prevalent in heart failure with preserved ejection fraction (HFpEF) and portends a worse clinical course. Unlike ventricular FMR, it lacks evidence-based treatment and is often overlooked. Sacubitril-valsartan may provide benefit in this HFpEF phenotype. OBJECTIVE: To assess the impact of sacubitril-valsartan on exercise hemodynamics in patients with HFpEF and atrial FMR. METHODS: This multicenter, prospective, randomized, open-label trial with blinded endpoint assessment enrolls patients with stable HFpEF and at least moderate FMR documented within 1 year prior to enrollment. Participants are randomly assigned to sacubitril-valsartan plus standard medical therapy or to standard therapy alone, consisting of a mineralocorticoid receptor antagonist and a sodium-glucose cotransporter-2 inhibitor. Cardiopulmonary exercise testing with echocardiography is performed at baseline and after 6 months, with interval 24-hour home blood pressure monitoring to ensure blood pressure control in both arms. The primary endpoint is the change in exercise-induced pulmonary hypertension, assessed by the change in the mean pulmonary arterial pressure to cardiac output slope. This slope reflects total pulmonary resistance driven by both pre- and postcapillary factors, capturing key HFpEF features, including myocardial properties, vascular remodeling and the overall impact of (dynamic) atrial FMR. Secondary endpoints include changes in FMR severity, peak oxygen consumption, natriuretic peptide levels, left atrial size and function, and patient-reported outcomes. Prespecified adverse events include hypotension, renal failure, hyperkalemia, and angioedema. CONCLUSION: The PRAISE-MR (Sacubitril-Valsartan in Heart Failure with Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation) trial will evaluate whether sacubitril-valsartan, an angiotensin receptor neprilysin inhibitor, is beneficial in patients with HFpEF and atrial FMR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureMitral Valve InsufficiencyStroke VolumeAminobutyratesTetrazolesNeprilysinAngiotensin Receptor AntagonistsHumansDrug CombinationsBiphenyl CompoundsValsartanProspective StudiesRandomized Controlled Trials as TopicMulticenter Studies as TopicFemaleMaleTreatment Outcome

Stichwörter der Autor:innen

Atrial function mitral regurgitationclinical trialheart failure with preserved ejection fractionsacubitril-valsartan

Substanzen

sacubitril and valsartan sodium hydrate drug combinationDrug CombinationsBiphenyl CompoundsAminobutyratesValsartanTetrazolesNeprilysinAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Department of Cardiology, Hospital Oost-Limburg, Genk, Belgium; Doctoral School of Medicine and Life Sciences, Limburg Clinical Research Center, Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgiu…
  • Doctoral School of Medicine and Life Sciences, Limburg Clinical Research Center, Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium; Department of Cardiology, Jessa Hospital, Hasselt, Belgium.
  • Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Jette, Belgium; Centre for Cardiovascular Diseases, University Hospital Brussels, Jette, Belgium.
  • Doctoral School of Medicine and Life Sciences, Limburg Clinical Research Center, Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.

Förderung

  • FWO

Zitieren

APA

Dhont, S., Ferreira, S. M., Galloo, X., Martens, P., Meekers, E., Tartaglia, K., Deferm, S., Herbots, L., Mullens, W., Verbrugge, F. H., Verwerft, J., & Bertrand, P. B. (2025). Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: Design and Rationale of the PRAISE-MR Trial. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2025.05.019

Vancouver

Dhont S, Ferreira SM, Galloo X, Martens P, Meekers E, Tartaglia K, et al. Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: Design and Rationale of the PRAISE-MR Trial. Journal of Cardiac Failure. 2025. doi:10.1016/j.cardfail.2025.05.019

BibTeX
@article{Dhont2025,
  author = {Dhont, Sebastiaan and Ferreira, Sara Moura and Galloo, Xavier and Martens, Pieter and Meekers, Evelyne and Tartaglia, Katrien and Deferm, Sébastien and Herbots, Lieven and Mullens, Wilfried and Verbrugge, Frederik H and Verwerft, Jan and Bertrand, Philippe B},
  title = {Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: Design and Rationale of the PRAISE-MR Trial},
  journal = {Journal of Cardiac Failure},
  year = {2025},
  doi = {10.1016/j.cardfail.2025.05.019}
}
Kostenlos starten →